SCHEMBL3341872

SCHEMBL3341872

O=C(NNc1nc(-c2ccc(Br)cc2)cs1)c1ccc2c(c1)OCO2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.61
MEN1 O00255 8/20 0.61
KMT2A Q03164 8/20 0.61
KDM4E B2RXH2 7/20 0.61
GAA P10253 6/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
ALDH1A1 P00352 5/20 0.61
HTT P42858 5/20 0.61
CFTR P13569 2/20 0.60
LMNA P02545 8/20 0.57
RAB9A P51151 5/20 0.57
HPGD P15428 1/20 0.56
MAPK1 P28482 2/20 0.55
TSHR P16473 1/20 0.55
NPC1 O15118 5/20 0.54
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
GSTO1 P78417 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3338101 0.89 MAPT (0.67) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3337373 0.87 PTGS2 (0.64) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL3341533 0.86 CA12 (0.54) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3344076 0.81 MAPT (0.66) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3339186 0.80 NPC1 (0.78) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3343782 0.79 MAPT (0.78) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3341958 0.79 MAPT (0.79) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3338658 0.78 MAPT (0.71) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3338729 0.76 CA12 (0.75) MAPTMEN1KMT2AKDM4EGAA
SCHEMBL3338623 0.76 MAPT (0.59) MAPTMEN1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885MEN1 1886/4885KMT2A 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.